EVO Quote, Financials, Valuation and Earnings

BioNTech SE has a net margin of -15.79% compared to Evotec SE's net margin of -227.46%. Evotec SE's return on equity of -20.84% beat BioNTech SE's return on equity of -3.91%.

Evotec SE has a consensus price target of $5.9933, signalling upside risk potential of 46.89%. On the other hand BioNTech SE has an analysts' consensus of $135.12 which suggests that it could grow by 28.58%. Given that Evotec SE has higher upside potential than BioNTech SE, analysts believe Evotec SE is more attractive than BioNTech SE.

Evotec SE has a beta of 1.656, which suggesting that the stock is 65.647% more volatile than S&P 500. In comparison BioNTech SE has a beta of 1.288, suggesting its more volatile than the S&P 500 by 28.759%.

Evotec SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evotec SE pays -- of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend.

Evotec SE quarterly revenues are $210.4M, which are larger than BioNTech SE quarterly revenues of $192.3M. Evotec SE's net income of -$33.2M is higher than BioNTech SE's net income of -$437.5M. Notably, Evotec SE's price-to-earnings ratio is -- while BioNTech SE's PE ratio is 191.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evotec SE is 1.71x versus 8.52x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.

CureVac NV has a net margin of -15.79% compared to Evotec SE's net margin of -5832.47%. Evotec SE's return on equity of -20.84% beat CureVac NV's return on equity of 32.68%.

Evotec SE has a consensus price target of $5.9933, signalling upside risk potential of 46.89%. On the other hand CureVac NV has an analysts' consensus of $5.92 which suggests that it could grow by 10.46%. Given that Evotec SE has higher upside potential than CureVac NV, analysts believe Evotec SE is more attractive than CureVac NV.

Evotec SE has a beta of 1.656, which suggesting that the stock is 65.647% more volatile than S&P 500. In comparison CureVac NV has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Evotec SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CureVac NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evotec SE pays -- of its earnings as a dividend. CureVac NV pays out -- of its earnings as a dividend.

Evotec SE quarterly revenues are $210.4M, which are larger than CureVac NV quarterly revenues of $939.6K. Evotec SE's net income of -$33.2M is higher than CureVac NV's net income of -$54.8M. Notably, Evotec SE's price-to-earnings ratio is -- while CureVac NV's PE ratio is 5.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evotec SE is 1.71x versus 2.10x for CureVac NV. Usually stocks with elevated PS ratios are considered overvalued.

InflaRx NV has a net margin of -15.79% compared to Evotec SE's net margin of -14092.9%. Evotec SE's return on equity of -20.84% beat InflaRx NV's return on equity of -56.78%.

Evotec SE has a consensus price target of $5.9933, signalling upside risk potential of 46.89%. On the other hand InflaRx NV has an analysts' consensus of $3.62 which suggests that it could grow by 352.26%. Given that InflaRx NV has higher upside potential than Evotec SE, analysts believe InflaRx NV is more attractive than Evotec SE.

Evotec SE has a beta of 1.656, which suggesting that the stock is 65.647% more volatile than S&P 500. In comparison InflaRx NV has a beta of 1.287, suggesting its more volatile than the S&P 500 by 28.694%.

Evotec SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InflaRx NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evotec SE pays -- of its earnings as a dividend. InflaRx NV pays out -- of its earnings as a dividend.

Evotec SE quarterly revenues are $210.4M, which are larger than InflaRx NV quarterly revenues of -$450. Evotec SE's net income of -$33.2M is lower than InflaRx NV's net income of -$8.7M. Notably, Evotec SE's price-to-earnings ratio is -- while InflaRx NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evotec SE is 1.71x versus 264.27x for InflaRx NV. Usually stocks with elevated PS ratios are considered overvalued.

Immatics NV has a net margin of -15.79% compared to Evotec SE's net margin of -214.48%. Evotec SE's return on equity of -20.84% beat Immatics NV's return on equity of -4.67%.

Evotec SE has a consensus price target of $5.9933, signalling upside risk potential of 46.89%. On the other hand Immatics NV has an analysts' consensus of $14.33 which suggests that it could grow by 163.48%. Given that Immatics NV has higher upside potential than Evotec SE, analysts believe Immatics NV is more attractive than Evotec SE.

Evotec SE has a beta of 1.656, which suggesting that the stock is 65.647% more volatile than S&P 500. In comparison Immatics NV has a beta of 0.827, suggesting its less volatile than the S&P 500 by 17.335%.

Evotec SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Immatics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evotec SE pays -- of its earnings as a dividend. Immatics NV pays out -- of its earnings as a dividend.

Evotec SE quarterly revenues are $210.4M, which are larger than Immatics NV quarterly revenues of $19.6M. Evotec SE's net income of -$33.2M is higher than Immatics NV's net income of -$41.9M. Notably, Evotec SE's price-to-earnings ratio is -- while Immatics NV's PE ratio is 42.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evotec SE is 1.71x versus 3.97x for Immatics NV. Usually stocks with elevated PS ratios are considered overvalued.